HTA of the Innovative Medicines in Germany

The Market Access of the innovative medicines is monitored by both Regulators and Payers. To assess the new drugs; if they deliver a fair value for money. The remarkable recent discrepancies between both parties’ requirements during the market entry process represent a financial threat on the Pharmaceutical industry. The evolving restrictions would alter the industry motive to invest in Research and Development. Consequently patients will not receive the appropriate medicines to win their battles against the developed ailments which may then contribute to a public health alarm.